Design, Synthesis and Anti‐Proliferative Assessment of 4‐Aminoquinoline‐ and 4‐Aminoquinoline‐Benzoxaborole Conjugates

A series of 4-aminoquinoline analogues and 4-aminoquinoline-benzoxaborole conjugates were synthesized and evaluated for their antiproliferative activities against two distinct breast cancer cell lines: MCF-7 (estrogen receptor-positive, ER+) and MDA-MB-231 (triple-negative). Preliminary dose-response assays revealed compound 5e, a 4-aminoquinoline-benzoxaborole conjugate, as the most active compound against MCF-7 cells. Structure-activity relationship (SAR) analysis indicated that the cytotoxic potency of the series increased with the length of the alkyl spacer connecting the pharmacophoric moieties. To assess selectivity, HEK-293 cells were employed as a non-cancerous control line, and most compounds exhibited minimal cytotoxicity, except compound 5d, which showed moderate effects. To gain preliminary structural insights, exploratory molecular docking studies were performed against the ligand-binding domain of estrogen receptor alpha (ERα). This integrated experimental-computational approach highlights the identification of promising preliminary hits. Overall, the findings show that 4-aminoquinoline-benzoxaborole conjugates exhibit antiproliferative activity against breast cancer cells, with greater potency towards MCF-7 cells.

Authors

Institutions

Publication Details

Journal
ChemMedChem
Published
2026-11-16
DOI
https://doi.org/10.1002/cmdc.70538
Primary Topic
Heterocyclic Compound Synthesis and Bioactivity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Design, Synthesis and Anti‐Proliferative Assessment of 4‐Aminoquinoline‐ and 4‐Aminoquinoline‐Benzoxaborole Conjugates

Raghu Raj, Mandeep Kaur, Vipan Kumar, Sumit Kumar et al.
ChemMedChem
Heterocyclic Compound Synthesis and Bioactivity
article

Design, Synthesis and Anti‐Proliferative Assessment of 4‐Aminoquinoline‐ and 4‐Aminoquinoline‐Benzoxaborole Conjugates

Raghu Raj, Mandeep Kaur, Vipan Kumar, Sumit Kumar, Sourav Taru Saha, Anu Saini
article en

Abstract

A series of 4-aminoquinoline analogues and 4-aminoquinoline-benzoxaborole conjugates were synthesized and evaluated for their antiproliferative activities against two distinct breast cancer cell lines: MCF-7 (estrogen receptor-positive, ER+) and MDA-MB-231 (triple-negative). Preliminary dose-response assays revealed compound 5e, a 4-aminoquinoline-benzoxaborole conjugate, as the most active compound against MCF-7 cells. Structure-activity relationship (SAR) analysis indicated that the cytotoxic potency of the series increased with the length of the alkyl spacer connecting the pharmacophoric moieties. To assess selectivity, HEK-293 cells were employed as a non-cancerous control line, and most compounds exhibited minimal cytotoxicity, except compound 5d, which showed moderate effects. To gain preliminary structural insights, exploratory molecular docking studies were performed against the ligand-binding domain of estrogen receptor alpha (ERα). This integrated experimental-computational approach highlights the identification of promising preliminary hits. Overall, the findings show that 4-aminoquinoline-benzoxaborole conjugates exhibit antiproliferative activity against breast cancer cells, with greater potency towards MCF-7 cells.

ChemMedChemVol. 21(22)
Guru Nanak Dev University (IN), University of the Witwatersrand (ZA), University of Bergen (NO)
Heterocyclic Compound Synthesis and Bioactivity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon